Bringing New Hope to Cancer Patients

Everyone knows someone who has cancer. Watching them struggle with the harsh side effects of chemotherapy or surgery, the challenges of trying various treatments, or the heartbreak of discovering their tumor is inoperable, can be agonizing for both patients and their families. 

At Intragel, we want to change this.

At Intragel, we are changing this.

About Us

We are pioneering a state-of-the-art, safe, and effective solution for life-threatening solid tumors using a localized intra-tumoral injectable drug delivery system, SRGel, that extends the release and efficacy of most anticancer medications.

Led by a team of highly professional and experienced scientists, and business executives, Intragel brings proven experience in bringing novel cancer therapies to market. The company operates from within the NGT technology incubator located in Nazareth Israel.

Our story

Intragel was conceived from the smart yet simple concept of making existing anticancer drugs more efficient, yet safe, through improved delivery.   

The inspiration for the technology came from our Co-founder and Member of the Board, Prof. Avi Domb. Now the Chief Scientist of Israel’s Ministry of Science and Technology, Avi co-invented and developed the FDA-approved Gliadel® wafer, a breakthrough delivery model, where the wafer was infused with the drug and administered during surgery, in the early 2000’s to treat brain cancer (glioblastoma).

Avi recognized that by enhancing targeting precision and simplifying administration for tumors throughout the body, he could transform cancer treatment. After 15 years of research, Avi developed a versatile hydrophobic gel polymer compatible with 95% of anticancer drugs, offering easy injectable administration beyond surgery.

Management

DR. PETER SIMAN,PhD CEO & Co-Founder 

CEO & Co-Founder

Dr. Christine Damouni-Warwar, PhD R&D and Production Manager

R&D and Production
Manager

NARMEEN MATTA Production, Lab & QA Manager

QA Manager

MAYA SHICK Clinical Research Project Manager

Clinical Research
Project Manager

Board of Directors

ZOHAR GENDLER Chairman of the Board

Chairman of the Board

PROF. AVI DOMB Co-Founder & Board Member

Co-Founder &
Board Member

ZEEV ZEHAVI, MBA Board Member

Board Member

AVNER GEVA Co-Founder & Board Member

Co-Founder &
Board Member

Scientific Advisory Board

PROFESSOR HENRY BRENM, MD   Cushing Professor of Neurosurgery, Johns Hopkins University, USA

Cushing Professor of Neurosurgery,
Johns Hopkins University, USA

DR. JORGE J NIEVA Associate Professor of Clinical Medicine, Keck School of Medicine at USC

Associate Professor of Clinical
Medicine, Keck School of
Medicine at USC

PROF. ARON POPOVTZER MD Head of Sharett Institute of Oncology, Israel

Head of Sharett Institute
of Oncology, Israel

DR. PETER SIMAN,PhD CEO & Co-Founder 
DR. PETER SIMAN,PhD

CEO & Co-Founder

Vast experience in project management and R&D in a wide range of chemistry based medical devices and polymers technology.

Holds a B.Sc and M.Sc in chemistry from the Hebrew University, PhD from Ben-Gurion University in Israel and conducted his post-doctorate at the University of California, Berkeley, USA.

NIZAR MASHAL CFO
NIZAR MISHAEL

CFO

Co-founder of NGT Fund I. Over 15 years experience as CFO of start-up companies: hands-on financial experience from seed investment to early and late financing rounds, with deep understanding of structuring complex investment and business interactions, in addition to financial and accounting expertise.

Dr. Christine Damouni-Warwar, PhD R&D and Production Manager
Dr. CHRISTINE WARWAR DAMOUNY

R&D and Production Manager

Over 8 years of experience in chemistry & materials sciences. Experienced researcher in tissue engineering and drug delivery. Holds a BSc and MSc in Chemistry and Material Sciences, and a PhD in the field of Chemical Engineering from the Technion Institute, Israel.

NARMEEN MATTA Production, Lab & QA Manager
NARMEEN MATTA

QA Manager

Experienced QC manager in the pharmaceuticals industry and GMP analysis and production. Holds a BSc in Chemistry from the Technion Institute, Israel.

MAYA SHICK Clinical Research Project Manager
MAYA SHICK

Clinical Research Project Manager

More than 15 years of experience in planning and managing global clinical trials in medical devices and pharmaceuticals. Served as a clinical trials manager, director, project manager and independent consultant in numerous Israeli companies.

ZOHAR GENDLER Chairman of the Board
ZOHAR GENDLER

Chairman of the Board

CEO & Managing Partner of NGT3VC and NGT Healthcare II. Led the establishment of and investment in more than 50 companies such as Prolor Biotech (sold to OPKO for $480M), Mazor Robotics (sold to Medtronic for $1.6B), ReWalk (NASDAQ: RWLK), Corindus (sold to Siemens Healthcare for $1.1B), and many others.

PROF. AVI DOMB Co-Founder & Board Member
PROF. AVI DOMB

Co-Founder & Board Member

Inventor of a dozen approved products bringing vast experience in pharmaceutical development and innovation. Holds a PhD in chemistry with undergraduate degrees in chemistry, pharmaceutics, and law.

He currently holds the prestigious role of Chief Scientist of Israel. During his career he was also the head of Pharmacy School at the Hebrew University of Jerusalem, the Head of Division of Identification and Forensic Sciences (DIFS), Israel police, Rank: Brigadier General.

ZEEV ZEHAVI, MBA Board Member
ZEEV ZEHAVI, MBA

Board Member

Extensive healthcare and business expertise. Held significant leadership roles in Teva Pharmaceuticals Industries and Clal Pharmaceutical Industries, and during the past 20 years as Vice President of Venture Investments for Johnson & Johnson Innovation.

AVNER GEVA Co-Founder & Board Member
AVNER GEVA

Co-Founder & Board Member

Entrepreneur in the life sciences. Founder and CEO of Vensica Medica. Led the company from conception through phase II clinical trials.  Headed successful funding rounds with VCs and strategics and in-licensed Xeomin®, an FDA approved biologic. Entrepreneur-in-residence, Yale University. Yale undergrad in Biology (BSc). Technion Biomedical Engineering (MSc).

NISSIM DARVISH, MD, DSc  Board Member
NISSIM DARVISH, MD, DSc

Board Member

Seasoned life science industry veteran, bringing valuable experience in medical technology development, corporate leadership and investment management. His roles include Senior Managing Director at OrbiMed, GM at Pitango and founder and former CEO of Impulse Dynamics.
PROFESSOR HENRY BRENM, MD   Cushing Professor of Neurosurgery, Johns Hopkins University, USA
PROFESSOR HENRY BREM, MD

Cushing Professor of Neurosurgery, Johns Hopkins University, USA

Prof. Brem is the Cushing Professor of Neurosurgery at The Johns Hopkins University, Director of the Department of Neurosurgery, Neurosurgeon-in-Chief, Professor of Oncology, Ophthalmology, and Biomedical Engineering and co-leader of the Brain Cancer Program for the Johns Hopkins Kimmel Cancer Center.

Prof. Brem worked with Prof. Avi Domb to develop the Gliadel wafer in the late 90s and early 2000s. He brings a wealth of knowledge and unmatched experience in bringing forward new technologies in the neurooncology and neurotechnology field.

DR. JORGE J NIEVA Associate Professor of Clinical Medicine, Keck School of Medicine at USC
DR. JORGE J NIEVA

Associate Professor of Clinical Medicine, Keck School of Medicine at USC

A distinguished alumnus of the University of California, Irvine College of Medicine, Dr. Nieva has consistently been at the forefront of oncology research. From pioneering technology for detecting cancer cells in the bloodstream to spearheading advancements in immunotherapy, his contributions to the medical community are significant.

He has held leadership roles at leading institutions including the Billings Clinic and currently at the Keck School of Medicine, and has published over 90 research papers in leading journals. His research teams have been awarded certificates for excellence in the conduct of cancer clinical trials from the National Cancer Institute and the American Society of Clinical Oncology. He is currently a standing member of the Oncology Drug Advisory Committee of the FDA.

PROF. ARON POPOVTZER MD Head of Sharett Institute of Oncology, Israel
PROF. ARON POPOVTZER, MD

Head of Sharett Institute of Oncology, Israel

A graduate of the Hadassah–Hebrew University School of Medicine, Prof. Popovtzer initially specialized in ear, nose, and throat (ENT). He then went into oncology and radiotherapy, pursuing a further specialization in head and neck cancer at the University of Michigan in Ann Arbor. From Michigan, Prof. Popovtzer moved to Beth Israel Medical Center in New York to gain experience in brachytherapy, which involves treating cancer by inserting radioactive implants directly into cancerous tissue.

During the last five years as deputy head of the oncology institute at Rabin Medical Center, Prof. Popovtzer was involved in both treatment and research. He has published some 75 articles.